Parataxis Holdings to Acquire Majority Stake in Bridge Biotherapeutics

According to BlockBeats, Parataxis Holdings LLC, an investment firm specializing in digital assets, has signed a definitive agreement to acquire a controlling interest in Bridge Biotherapeutics, Inc. through Parataxis Korea Fund I LLC and its affiliates. The investment amounts to 25 billion Korean won. Upon completion of the transaction, the company plans to change its name to Parataxis Korea and remain listed on KOSDAQ. The deal is subject to customary closing conditions, including shareholder approval. This acquisition will establish a Bitcoin-centric reserve platform in the Korean public market, backed by institutional investors with extensive experience in digital asset investments. As part of the transaction, Edward Chin, founder and CEO of Parataxis Holdings and co-founder and CEO of Parataxis Capital, will join the company's board of directors. Andrew Kim, a partner at Parataxis Capital, will become the company's CEO and also join the board. James Jungkue Lee, co-founder of Bridge Bio, will continue to lead the core biotechnology business and retain his board seat.